Tarsus Pharmaceuticals (TARS) Work In Process (2023 - 2026)

Tarsus Pharmaceuticals' Work In Process history runs 4 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Work In Process rose 113.61% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 113.61% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 129.64% from the prior year.
• Work In Process climbed to $1.6 million in Q1 2026 per TARS's latest filing, from $1.4 million in the prior quarter.
• Across five years, Work In Process topped out at $1.6 million in Q1 2026 and bottomed at $392000.0 in Q4 2023.
• The 4-year median for Work In Process is $1.1 million (2024), against an average of $1.1 million.
• Biggest YoY gain for Work In Process was 129.64% in 2025; the steepest drop was 37.12% in 2025.
• Year by year, Work In Process stood at $392000.0 in 2023, then soared by 56.63% to $614000.0 in 2024, then jumped by 129.64% to $1.4 million in 2025, then gained by 15.74% to $1.6 million in 2026.
• Per Business Quant, the three latest TARS Work In Process figures stand at $1.6 million (Q1 2026), $1.4 million (Q4 2025), and $1.0 million (Q3 2025).